ReviewProgress in neurobiology2008
Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies.
Review in Progress in neurobiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 109 citations in OpenAlex.
- Expression of erythropoietin receptor protein in the mouse hippocampus in response to normobaric hypoxia.Heliyon · 2024Article
- Probiotic Potential of Bacillus amyloliquefaciens Isolated from Tibetan Yaks.Probiotics and antimicrobial proteins · 2024Article
- Drug Utilization Evaluation of Erythropoietin at a Referral Teaching Hospital in Iran.Advances in pharmacological and pharmaceutical sciences · 2023Article
- The sirtuin family in health and disease.Signal transduction and targeted therapy · 2022Review
- Therapeutic Effect of Erythropoietin on Alzheimer's Disease by Activating the Serotonin Pathway.International journal of molecular sciences · 2022Article
- Erythropoietin promotes M2 macrophage phagocytosis of Schwann cells in peripheral nerve injury.Cell death & disease · 2022Article
- Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements inFrontiers in immunology · 2021Article
- Effect of simulated microgravity on metabolism of HGC-27 gastric cancer cells.Oncology letters · 2020Article
- Integration of probabilistic regulatory networks into constraint-based models of metabolism with applications to Alzheimer's disease.BMC bioinformatics · 2019Article
- Potential use of transgenic domestic pigs expressing recombinant human erythropoietin in diabetes translation research.Animal cells and systems · 2019Article
- FOXO Signaling Pathways as Therapeutic Targets in Cancer.International journal of biological sciences · 2017Review
- Age-associated expression of erythropoietin and its receptor in rat spiral ganglion neurons and its association with neuronal apoptosis and hearing alterations.Molecular medicine reports · 2017Article
- Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution.Nature communications · 2016Article
- Charting a course for erythropoietin in traumatic brain injury.Journal of translational science · 2016Article
- Regeneration in the nervous system with erythropoietin.Frontiers in bioscience (Landmark edition) · 2016Review
- Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.Current neurovascular research · 2016Review
- Erythropoietin and diabetes mellitus.World journal of diabetes · 2015Review
- Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease.Neural regeneration research · 2015Review
- Erythropoietin attenuates advanced glycation endproducts-induced toxicity of Schwann cells in vitro.Neurochemical research · 2015Article
- mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus.World journal of diabetes · 2015Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Given that erythropoietin (EPO) is no longer believed to have exclusive biological activity in the hematopoietic system, EPO is now considered to have applicability in a variety of nervous system disorders that can overlap with vascular disease, metabolic impairments, and immune system function. As a result, EPO may offer efficacy for a broad number of disorders that involve Alzheimer's disease, cardiac insufficiency, stroke, trauma, and diabetic complications. During a number of clinical conditions, EPO is robust and can prevent metabolic compromise, neuronal and vascular degeneration, and inflammatory cell activation. Yet, use of EPO is not without its considerations especially in light of frequent concerns that may compromise clinical care. Recent work has elucidated a number of novel cellular pathways governed by EPO that can open new avenues to avert deleterious effects of this agent and offer previously unrecognized perspectives for therapeutic strategies. Obtaining greater insight into the role of EPO in the nervous system and elucidating its unique cellular pathways may provide greater cellular viability not only in the nervous system but also throughout the body.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.